Anticancer drugs
 Add to favourites!!!

Anticancer drugs






Anticancer drugs

  Abstract TEMPLATE
  Download the program as PDF






Advisory Board Member

Maurizio Memo, PhD

Professor of Pharmacology
Vice-Chancellor, University of Brescia
University of Brescia Medical School
Viale Europa 11,
25123 Brescia, Italy



Professor of Pharmacology

Director, Department of Biomedical Sciences and Biotechnologies, University of Brescia Medical School, Brescia, Italy


Education. 1977 Graduated in Chemistry and Pharmaceutical Technology at the University of Cagliari, Italy

1980 Residency in Pharmacology, University of Milan, Milan, Italy


Position and employment. 1980-1982 Research fellow, at the National Heart, Lung and Blood Institute, Section on Biochemical Pharmacology, National Institute of Health, Bethesda, MD, USA. 1983-1988 Researcher of Pharmacology, at the University of Cagliari, Italy. 1988-1990 Visiting Associate Professor of Pharmacology, Georgetown University Medical School, Washington D.C., USA. 1988-2000 Associate Professor of Pharmacology, at the University of Brescia, Italy. 2000- present Full Professor of Pharmacology, at the University of Brescia, Italy.


Other Experience and Professional Membership. 1980- Member Society of Italian Pharmacology (SIF). 1985- Member, American Society of Neuroscience. 1988-2000 Professor Neuropsycopharmacology, University of Brescia, Italy. 1990- Member Society of Italian Neuroscience (SIN). 1991- Founder and President of the Italian Group of Molecular Neurobiology. 1994- Professor Faculty PhD program in Neuroscience. 1995- Founder and Vice-President of the European School of Molecular Medicine. 1996- Professor Faculty Residency in  Pharmacology. 1998- Associate Editor of "Functional Neurology" . 2000- Chief Molecular Neuropharmacology Laboratory, University of Brescia, Italy. 2000- Full Professor of Pharmacology, University of Brescia Medical School. 2002 Owner of a patent entitled "Useful compound for the treatment of neurodegenerative disease". 2003 Owner of a patent entitled "Method for early identification of Alzheimer's Disease". 2005 Member of the Editorial Board of "CNS Drug Review". 2007 Associated Editor of  "BMC Pharmacology"


Current research interests:

Neuropharmacology, role of Dopamine systems in schizophrenia and Parkinson's disease, molecular mechanisms of neurodegeneration, genetic and molecular risk factors for Alzheimer's disease; molecular mechanisms associated with neuroblastoma growth. 


Description of the main domain of research:

  • Identification and characterization of different DA receptor subtypes (named D1 and D2) in CNS and periphery (1978-1988)

  • Characterization of DA receptor function in schizophrenic brain (1980-1983)

  • Characterization of the transcriptional activity induced by glutamate receptor stimulation (1988-1991)

  • Characterization of the physiopathological role of the NF-kappaB pathway in the CNS (1993-present  

  • Discovery of neuroprotective activity of Aspirin and other anti-inflammatory drugs (1995-1998)

  • Identification of p53 as a novel participant in neurodegenerative process (1997-present)

  • Characterization of the physiopathological role of DNA damage repair systems in neurodegenerative diseases (1998-2008)

  • Identification of p53 as a possible biomarker for Alzheimer disease (2000-present)





Anticancer drugs

Anticancer drugs conferences 2011 2013                                        Powered by